Pharmaron Beijing Co., Ltd. released its monthly return for the period ended 30 April 2026, reporting no movements in authorised, issued, or treasury shares across its dual-listed share classes.

Key takeaways

1. Authorised share capital • H shares remained at 359.98 million with a par value of RMB 1 each. • A shares stood unchanged at 1.48 billion, also at RMB 1 par. • Combined authorised share capital was RMB 1.84 billion.

2. Issued and treasury shares • Issued H shares (excluding treasury) held steady at 352.71 million, while treasury H shares stayed at 7.26 million—previously repurchased in December 2024 and January 2025 and earmarked for the 2025 H Share Award and Trust Scheme. • Issued A shares were unchanged at 1.48 billion, with no treasury stock.

3. Equity incentive schemes in force • 2022 Restricted A Share Incentive Scheme: up to 0.68 million A shares remain issuable. • 2023 A Share Incentive Scheme: up to 0.91 million A shares remain issuable. • 2025 H Share Award and Trust Scheme: 7.26 million treasury H shares may be granted to employees.

4. Public float The company confirmed compliance with the Main Board’s minimum public-float requirement of 5 % of the issued H-share class (excluding treasury shares).

No share options, warrants, or convertible securities were outstanding or exercised during the month, and no other share capital adjustments occurred. The filing was signed by Company Secretary Mak Po Man Cherie on 6 May 2026.